why choose us

First received: August 19, 2022

Clinical Trial: Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Myelodysplastic Syndrome
Recurrent Myelodysplastic Syndrome
Refractory Myelodysplastic Syn

Study Type: INTERVENTIONAL


Official Title: A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Brief Summary: This trial tests the safety, side effects, and best dose of navitoclax in combination with venetoclax and decitabine in treating patients with higher risk myelodysplastic syndrome (MDS) that has come back after initial treatment or was not responsive to initial treatment. This study will also look at the effectiveness of the treatment combination and patient's quality of life while on these medications. Navitoclax is an oral drug that works as an inhibitor of the BCL-2 family of proteins, which are often overly…

Read more